Your browser doesn't support javascript.
loading
Altered somatic hypermutation patterns in COVID-19 patients classifies disease severity
Modi Safra; Zvi Tamari; Pazit Polak; Shachaf Shiber; Moshe Matan; Hani Karameh; Yigal Helviz; Adva Levy-Barda; Vered Yahalom; Avi Peretz; Eli Ben-Chetrit; Baruch Brenner; Tamir Tuller; Meital Gal-Tanamy; Gur Yaari.
Affiliation
  • Modi Safra; Bar Ilan University, Ramat Gan, Israel
  • Zvi Tamari; Bar Ilan University, Ramat Gan, Israel
  • Pazit Polak; Bar Ilan University, Ramat Gan, Israel
  • Shachaf Shiber; Tel Aviv University, Tel Aviv, Israel
  • Moshe Matan; Baruch Padeh Medical Center, Poriya, Israel
  • Hani Karameh; Hebrew University School of Medicine, Jerusalem, Israel
  • Yigal Helviz; Hebrew University School of Medicine, Jerusalem, Israel
  • Adva Levy-Barda; Rabin Medical Center- Belinson campus, Petah Tikva, Israel
  • Vered Yahalom; Tel Aviv University, Tel Aviv, Israel
  • Avi Peretz; Bar-Ilan University, Safed, Israel
  • Eli Ben-Chetrit; Hebrew University School of Medicine, Jerusalem, Israel
  • Baruch Brenner; Rabin Medical Center- Belinson campus, Petah Tikva, Israel
  • Tamir Tuller; Tel Aviv University, Tel Aviv, Israel
  • Meital Gal-Tanamy; Bar-Ilan University, Safed, Israel
  • Gur Yaari; Bar Ilan University, Ramat Gan, Israel
Preprint in En | PREPRINT-BIORXIV | ID: ppbiorxiv-521139
ABSTRACT
The success of the human body in fighting SARS-CoV-2 infection relies on lymphocytes and their antigen receptors. Identifying and characterizing clinically relevant receptors is of utmost importance. We report here the application of a machine learning approach, utilizing B cell receptor repertoire sequencing data from severely and mildly infected individuals with SARS-CoV-2 compared with uninfected controls. In contrast to previous studies, our approach successfully stratifies non-infected from infected individuals, as well as disease level of severity. The features that drive this classification are based on somatic hypermutation patterns, and point to alterations in the somatic hypermutation process in COVID-19 patients. These features may be used to build and adapt therapeutic strategies to COVID-19, in particular to quantitatively assess potential diagnostic and therapeutic antibodies. These results constitute a proof of concept for future epidemiological challenges.
License
cc_by_nc
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2022 Document type: Preprint
Full text: 1 Collection: 09-preprints Database: PREPRINT-BIORXIV Language: En Year: 2022 Document type: Preprint